Boston, MA -- (SBWIRE) -- 09/09/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (VIVUS, Inc.(NASDAQ:VVUS), ReneSola Ltd. (ADR) (NYSE:SOL), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)
VIVUS, Inc.(NASDAQ:VVUS) shares declined 1.27% to $10.82. The company on Sept. 4 said new Chief Executive Officer Tony Zook has resigned because of health reasons. Seth H. Z. Fischer, formerly with Johnson & Johnson (JNJ), will replace Zook immediately, the Mountain View, California-based company said today in a statement.
Additionally, the company on August 6 reported its financial results for the quarter ended June 30, 2013. Net product revenue from sales of Qsymia in the first half of 2013 was $9.6 million. For the six months ended June 30, 2013, we reported a net loss of $109.1 million, or $1.08 net loss per share, as compared to a net loss of $42.8 million, or $0.45 net loss per share during the first half of 2012.
How Should Investors Trade VVUS After The Recent Volatility? Get Free Report Here
ReneSola Ltd. (ADR) (NYSE:SOL) shares gained 0.87% to $5.77. The company on August 30 said its second-quarter loss narrowed, benefiting from higher selling prices of solar wafers and modules. For the period ended June 30, the company lost $21.1 million, or 24 cents per American depositary share. That compares with a loss of $34.8 million, or 40 cents per ADS, a year ago. Revenue soared 62% to $377.4 million from $233 million.
Looking forwatd, the company anticipates third-quarter revenue of $360 million to $380 million.
How Should Investors Trade SOL After The Recent Volatility? Get Free Report Here
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares climbed 7.66% to $23.05. The company on August 19 announced the appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer, effective today. Mr. Moore reports to ACADIA's Chief Executive Officer, Uli Hacksell, Ph.D., and will be responsible for leading ACADIA's commercial activities.
Additionally, the company on August 6 reported a net loss of $9.1 million, or $0.11 per common share, for the second quarter of 2013 compared to a net loss of $5.4 million, or $0.10 per common share, for the second quarter of 2012.
Is ACAD A Good Buy After The Recent Price Movement? Find Out Here
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) shares gained 0.34% to $8.76. Shareholder rights attorneys at Robbins Arroyo LLP on Sept. 5 are investigating the acquisition of Astex Pharmaceuticals, Inc. by Otsuka Pharmaceutical Co., Ltd. ("Otsuka"). On September 5, 2013, the two companies announced the signing of a definitive merger agreement under which Otsuka will acquire Astex for $8.50 per share in cash. The transaction is expected to close in the fourth quarter of 2013.
Additionally, the company, on August 28, announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course.
Is ASTX A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)